Humedix Selected for Government Support to Establish COVID-19 Vaccine Production Facilities

In August, the technical team from the Russian Sovereign Wealth Fund (RDIF) visited Humedix's second factory in Jecheon, Chungbuk, touring the production facilities with Humedix officials. (Photo by Humedix)

[Asia Economy Reporter Lee Chun-hee] Humedix has been selected as a recipient of the government’s support for COVID-19 vaccine production facilities and equipment.

On the 22nd, Humedix announced that it was finally selected as a target for the ‘COVID-19 Vaccine Production and Raw Material Facilities and Equipment Support Project’ hosted by the Ministry of Health and Welfare and the Korea Health Industry Development Institute.

Humedix is participating in the contract manufacturing organization (CMO) consortium for the Russian COVID-19 vaccine ‘Sputnik V’ by Huons Global, handling vial filling and finished product packaging. While the Huons Global consortium aims to produce more than 100 million doses per month, Humedix is also pushing to expand the vial line at its second plant in Jecheon-si, Chungbuk Province accordingly.

The Ministry of Health and Welfare and the Health Industry Development Institute secured an additional budget of 18 billion KRW to support the early establishment of a global vaccine production hub by supporting domestic companies in building COVID-19 vaccine production and raw material facilities and equipment. Eligible companies are those that have manufacturing facilities and technology capable of contract or self-production of COVID-19 vaccines and raw materials or can demonstrate vaccine production capacity.

A Humedix official explained, “We were selected for this government support project due to excellent production facilities and capacity, expertise of research personnel, and recruitment of new staff for vaccine manufacturing.” The company plans to use the 960 million KRW in support funds secured through this project for operating expenses related to ongoing pilot production and full-scale operation of the expanded line.

Jinhwan Kim, CEO of Humedix, said, “Since we have received financial support from the government, we will do our best in producing the Sputnik V vaccine to contribute to the end of COVID-19 worldwide and the leap of South Korea as a global vaccine production hub.”